SG11201900744SA - Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them - Google Patents
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using themInfo
- Publication number
- SG11201900744SA SG11201900744SA SG11201900744SA SG11201900744SA SG11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- johnson
- rule
- methods
- superfamily member
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662374347P | 2016-08-12 | 2016-08-12 | |
PCT/US2017/045466 WO2018031400A1 (en) | 2016-08-12 | 2017-08-04 | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900744SA true SG11201900744SA (en) | 2019-02-27 |
Family
ID=61158615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900744SA SG11201900744SA (en) | 2016-08-12 | 2017-08-04 | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
Country Status (11)
Country | Link |
---|---|
US (2) | US20180044430A1 (ja) |
EP (1) | EP3497126A4 (ja) |
JP (2) | JP7009448B2 (ja) |
KR (1) | KR102554331B1 (ja) |
CN (1) | CN109843916B (ja) |
AU (1) | AU2017308734A1 (ja) |
CA (1) | CA3033665A1 (ja) |
IL (1) | IL264515A (ja) |
MA (1) | MA45941A (ja) |
SG (1) | SG11201900744SA (ja) |
WO (1) | WO2018031400A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2953634T3 (da) | 2013-02-07 | 2021-08-30 | Massachusetts Gen Hospital | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler |
KR102410778B1 (ko) | 2016-05-13 | 2022-06-21 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
BR112019022752A2 (pt) | 2017-08-03 | 2020-05-19 | Alector Llc | anticorpos anti-trem2 e métodos de uso dos mesmos |
JP7250766B2 (ja) | 2017-08-25 | 2023-04-03 | ヤンセン バイオテツク,インコーポレーテツド | FCγRII結合フィブロネクチンIII型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子 |
EP3840782A4 (en) * | 2018-08-20 | 2022-06-08 | The General Hospital Corporation | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTAGONIST POLYPEPTIDES |
AU2019342017A1 (en) * | 2018-09-18 | 2021-05-13 | Merrimack Pharmaceuticals, Inc. | Anti-TNFR2 antibodies and uses thereof |
RU2734432C1 (ru) * | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
CN112574315B (zh) * | 2019-09-30 | 2023-04-07 | 广东菲鹏制药股份有限公司 | 改变效应功能的Fc变体及其融合蛋白 |
WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
BR112023020622A2 (pt) | 2021-04-25 | 2023-12-05 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1975182A1 (en) | 2000-02-01 | 2008-10-01 | PanGenetics B.V. | CD40-binding APC-activating molecules |
WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
CA2525717A1 (en) | 2003-05-23 | 2004-12-09 | Wyeth | Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
WO2006104989A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
BRPI0610470A2 (pt) | 2005-05-26 | 2010-06-22 | Seattle Genetics Inc | anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
WO2009085462A1 (en) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
CA2791658C (en) | 2010-03-04 | 2019-10-01 | Macrogenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
NZ623807A (en) | 2010-04-13 | 2016-03-31 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
SG184427A1 (en) | 2010-04-20 | 2012-11-29 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
MY171312A (en) | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
AU2012299421B2 (en) | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
PL2773671T3 (pl) | 2011-11-04 | 2022-01-24 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc |
AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
EA201500741A1 (ru) | 2013-01-10 | 2016-01-29 | Генмаб Б.В. | ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ |
CA2907140A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Biotech, Inc. | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins |
SG11201507781VA (en) * | 2013-03-18 | 2015-10-29 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
TW201534623A (zh) * | 2013-06-14 | 2015-09-16 | Bayer Pharma AG | 抗-tweakr抗體及其用途 |
MA40871A (fr) * | 2014-10-29 | 2017-09-05 | Novartis Ag | Expression directe d'anticorps |
JP7179464B2 (ja) * | 2015-01-20 | 2022-11-29 | アイジーエム バイオサイエンシズ インコーポレイテッド | 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用 |
CN107709364A (zh) * | 2015-04-07 | 2018-02-16 | 豪夫迈·罗氏有限公司 | 具有激动剂活性的抗原结合复合体及使用方法 |
SG11201803956UA (en) | 2015-12-01 | 2018-06-28 | Genmab Bv | Anti-dr5 antibodies and methods of use thereof |
MX2019001458A (es) * | 2016-08-02 | 2019-07-04 | Visterra Inc | Polipeptidos modificados y usos de los mismos. |
-
2017
- 2017-08-04 AU AU2017308734A patent/AU2017308734A1/en active Pending
- 2017-08-04 US US15/668,895 patent/US20180044430A1/en not_active Abandoned
- 2017-08-04 CN CN201780063333.0A patent/CN109843916B/zh active Active
- 2017-08-04 CA CA3033665A patent/CA3033665A1/en active Pending
- 2017-08-04 KR KR1020197007003A patent/KR102554331B1/ko active IP Right Grant
- 2017-08-04 MA MA045941A patent/MA45941A/fr unknown
- 2017-08-04 SG SG11201900744SA patent/SG11201900744SA/en unknown
- 2017-08-04 WO PCT/US2017/045466 patent/WO2018031400A1/en unknown
- 2017-08-04 JP JP2019507248A patent/JP7009448B2/ja active Active
- 2017-08-04 EP EP17840053.7A patent/EP3497126A4/en active Pending
-
2019
- 2019-01-28 IL IL264515A patent/IL264515A/en unknown
-
2020
- 2020-04-06 US US16/840,830 patent/US11359029B2/en active Active
-
2021
- 2021-11-11 JP JP2021184366A patent/JP2022033769A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200231693A1 (en) | 2020-07-23 |
WO2018031400A1 (en) | 2018-02-15 |
JP2022033769A (ja) | 2022-03-02 |
JP7009448B2 (ja) | 2022-02-10 |
MA45941A (fr) | 2019-06-19 |
JP2019532025A (ja) | 2019-11-07 |
KR102554331B1 (ko) | 2023-07-10 |
EP3497126A1 (en) | 2019-06-19 |
CN109843916B (zh) | 2023-10-31 |
IL264515A (en) | 2019-02-28 |
EP3497126A4 (en) | 2020-04-08 |
CA3033665A1 (en) | 2018-02-15 |
US11359029B2 (en) | 2022-06-14 |
US20180044430A1 (en) | 2018-02-15 |
CN109843916A (zh) | 2019-06-04 |
KR20190038629A (ko) | 2019-04-08 |
AU2017308734A1 (en) | 2019-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900744SA (en) | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201903693QA (en) | Polypeptide variants and uses thereof | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201908847TA (en) | Apparatuses, systems and methods for imaging flow cytometry | |
SG11201810687SA (en) | Serum albumin-binding fibronectin type iii domains | |
SG11201906961UA (en) | Polypeptide variants and uses thereof | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity |